KRAS and cancer: To promote cancer invasion, metastasis and immune evasion in pancreatic cancer, oncogenic KRAS cooperates indirectly with mutant p53 to induce overexpression of ARF6 and its effector AMAP1, involved in regulation of integrins and E-cadherin [47].